Brief: Larimar Therapeutics Provides Updates On CTI-1601 Clinical Program

Larimar Therapeutics

11/08/2022 22:35

Aug 11 (Reuters) - Larimar Therapeutics Inc  LRMR.O :
    * LARIMAR THERAPEUTICS PROVIDES UPDATES ON CTI-1601 CLINICAL
PROGRAM FOLLOWING A TYPE C MEETING WITH THE U.S. FOOD AND DRUG
ADMINISTRATION AND REPORTS SECOND QUARTER 2022 OPERATING AND
FINANCIAL RESULTS
    * LARIMAR THERAPEUTICS INC - PLANS TO SUBMIT A COMPLETE
RESPONSE
TO CTI-1601'S CLINICAL HOLD IN Q3 OF 2022
    * LARIMAR-WITH COMPLETE RESPONSE, CO PROPOSING PHASE 2,
4-WEEK
DOSE EXPLORATION STUDY IN FRIEDREICH'S ATAXIA PATIENTS AS
CTI-1601'S NEXT CLINICAL TRIAL
    * LARIMAR THERAPEUTICS INC - CASH AND MARKETABLE DEBT
SECURITIES
AT JUNE 30, 2022 OF $54.9 MILLION
    * LARIMAR THERAPEUTICS INC -  CASH AND MARKETABLE DEBT
SECURITIES
PROVIDES PROJECTED CASH RUNWAY THROUGH Q3 OF 2023

Source text for Eikon:  ID:nGNX7D23fP 
Further company coverage:  LRMR.O 

 ((Reuters.Briefs@thomsonreuters.com;))